Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
通过靶向NGS评估的肿瘤突变负荷可预测非小细胞肺癌患者从免疫检查点抑制剂治疗中获益。
期刊:Journal of Pathology
影响因子:5.2
doi:10.1002/path.5344
Alborelli, Ilaria; Leonards, Katharina; Rothschild, Sacha I; Leuenberger, Laura P; Savic Prince, Spasenija; Mertz, Kirsten D; Poechtrager, Severin; Buess, Martin; Zippelius, Alfred; Läubli, Heinz; Haegele, Jasmin; Tolnay, Markus; Bubendorf, Lukas; Quagliata, Luca; Jermann, Philip
